Introduction
============

Colorectal cancer (CRC) is one of the most common malignancies in industrialized countries and one of the most common causes of cancer-related death.[@b1-clep-3-027],[@b2-clep-3-027] In Denmark, approximately 4200 new cases of CRC are diagnosed each year,[@b3-clep-3-027] with a 5-year survival of only 43%--49%.[@b4-clep-3-027],[@b5-clep-3-027] Danish CRC survival is lower than in our neighboring counterparts and countries with similar health systems,[@b6-clep-3-027],[@b7-clep-3-027] probably due to higher mortality in the first year after diagnosis.[@b5-clep-3-027],[@b6-clep-3-027],[@b8-clep-3-027]

Similar to CRC, Denmark has lower survival for many other cancer sites.[@b5-clep-3-027],[@b6-clep-3-027],[@b9-clep-3-027] Aiming to improve cancer control, the first National Cancer Plan was established in 2000.[@b10-clep-3-027] The main topics were expansion of the diagnostic and nonsurgical treatment capacity, as well as establishment of multidisciplinary cancer groups and implementation of clinical databases in order to monitor quality of cancer treatment. In 2005, the second National Cancer Plan was launched[@b11-clep-3-027] and concerned the reduction of diagnostic and treatment delays by organizing the cancer pathways, as well as strengthening the cancer surgery by centralization and in-service training. Although these different initiatives may have the potential of improving survival in CRC patients, no updated data on survival exist. We therefore conducted the present study to monitor survival and mortality in colon and rectal cancer patients using existing data from the central and northern Danish regions.

Material and methods
====================

We conducted this study in the central and northern Denmark regions with a combined population of 1.8 million persons. The National Health Service provides tax-supported health care for all inhabitants of Denmark, guaranteeing free access to general practitioners and hospitals.

Identification of CRC patients
------------------------------

Through the Danish National Registry of Patients (DNRP), we identified all patients who had a first-time hospitalization with colon or rectal cancer between January 1, 1998 and December 31, 2009. The DNPR includes data on personal identification number, hospital, department, surgical and diagnostic procedures, and discharge diagnoses, as defined by the International Classification of Diseases 10th edition (ICD-10) by 1993.[@b12-clep-3-027] The ICD-10 codes used to identify colonic cancer were C18--19 and rectal cancer C20--21.

Survival
--------

Since 1968, the Central Office of Civil Registration has assigned a unique 10-digit civil registration number to all Danish citizens,[@b13-clep-3-027] which enables unambiguous data linkage between Danish registries. The Civil Registration System also contains information on vital status, date of death, and residence.

Statistical analysis
--------------------

We followed each patient from the date of colon or rectal cancer diagnosis until emigration, death, or June 25th 2010, whichever came first. To visualize crude survival we constructed Kaplan--Meier curves stratified according to periods of colon or rectal cancer diagnosis (1998--2000, 2001--2003, 2004--2006, and 2007--2009), estimating 1- and 5-year survival. In the latter periods we predicted 5-year survival using a hybrid analysis in which we included the actual survival for as long as possible and then estimated the conditional probability of surviving thereafter based on the corresponding survival experience of patients in the previous period (ie, using a period analysis technique).[@b14-clep-3-027] To compare mortality over time we used Cox proportional hazards regression analysis with 1998--2000 as a reference to estimate 1- and 5-year mortality rate ratios (MRRs) and the corresponding 95% confidence intervals (CIs) adjusting for age groups (15--64 years, 65--79 years, 80+ years) and gender. Additionally, analyses were stratified on age and gender. For the patients who underwent surgery, we likewise computed 30-day mortality rates for the four time periods. Surgery was defined as resection or first operative procedure, although the latter included resections if these were initially performed (see [Appendix 1](#app1-clep-3-027){ref-type="app"} for codes). First operative procedure also included defunctional procedures and/or definitive palliative procedures. Thus, a patient could enter both surgery groups in the case of an initial defunctional procedure and a resection hereafter. We used Cox proportional hazards regression analysis and estimated 30-day MRRs with 1998--2000 as a reference, adjusting for age and gender. Analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC).

Results
=======

Colon cancer
------------

A total of 9412 patients were diagnosed with colon cancer in the 1998--2009 period. The number of colon cancer patients increased from a total of 2097 in 1998--2000 to 2763 in 2007--2009 ([Table 1](#t1-clep-3-027){ref-type="table"}), most pronounced among men ([Table 2](#t2-clep-3-027){ref-type="table"}). At the same time median age at diagnosis declined from 73 years to 72 years. One-year overall survival improved from 65% to 70% over the study period, corresponding to an adjusted MRR of 0.83 (95% CI: 0.76--0.92) in 2007--2009 using 1998--2000 as a reference ([Figure 1](#f1-clep-3-027){ref-type="fig"} and [Table 1](#t1-clep-3-027){ref-type="table"}). Accordingly, the 5-year overall survival improved from 37% to predicted 43%, corresponding to a 5-year adjusted MRR of 0.84 (95% CI: 0.78--0.90) in 2007--2009 compared with 1998--2000. In general, in both genders and in all age groups the survival improved. Five-year survival improved particularly in men aged 15--64 and 80+ as well as in women aged 80+ ([Table 2](#t2-clep-3-027){ref-type="table"}).

The 30-day postoperative mortality decreased during the study period; after resection from 9% in 1998--2000 to 7% in 2007--2009 (adjusted MRR 0.68 (95% CI: 0.53--0.87)) and after the first operative procedure from 11% to 8% (adjusted MRR 0.71 (95% CI: 0.57--0.88)) ([Table 3](#t3-clep-3-027){ref-type="table"}).

Rectal cancer
-------------

A total of 5685 patients were diagnosed with rectal cancer in the 1998--2009 period. The number of rectal cancer patients increased during the four time intervals from a total of 1336 to 1554 ([Table 1](#t1-clep-3-027){ref-type="table"}), most pronounced among the youngest men and women ([Table 2](#t2-clep-3-027){ref-type="table"}). At the same time, median age at diagnosis declined from 71 years to 69 years. The 1-year overall survival improved from 73% to 78%, corresponding to an adjusted MRR of 0.79 (95% CI: 0.68--0.91) in 2007--2009 using 1998--2000 as a reference ([Figure 1](#f1-clep-3-027){ref-type="fig"} and [Table 1](#t1-clep-3-027){ref-type="table"}). Accordingly, the 5-year survival improved from 39% 1998--2000 to the predicted 47% in 2007--2009, corresponding to an adjusted MRR of 0.81 (95% CI: 0.73--0.89). In general, improvements in survival were present in all age groups in both genders apart from 1-year survival in women aged 80+. Men aged 80+ showed remarkable improvements in 1- and 5-year survival, whereas 5-year survival also improved notably in both genders aged 65--79 ([Table 4](#t4-clep-3-027){ref-type="table"}).

As for colon cancer patients, the 30-day postoperative mortality decreased for rectal cancer patients over the study period. After resection, 30-day mortality decreased from 5% in 1998--2000 to 3% in 2007--2009 (adjusted MRR of 0.59 (95% CI 0.37--0.96)), and after the first operative procedure the 30-day mortality decreased from 7% to 4% (adjusted MRR of 0.61 (95% CI 0.41--0.89)) ([Table 3](#t3-clep-3-027){ref-type="table"}).

Discussion
==========

In this large population-based study we found an improved survival in both colon and rectal cancer patients. Accordingly, the 30-day postoperative mortality also decreased for both cancer locations.

The main strength of this study is the population-based design with a large sample size covering about 30% of the Danish population and a complete hospital history. We had complete follow-up on all patients ensured by the Civil Registration System. These features minimize the risk of selection bias. We used the DNRP since it is continuously updated and has been demonstrated to be complete and valid.[@b15-clep-3-027],[@b16-clep-3-027] We consider overall survival as a valid outcome measurement in this study of prognostic changes over time, rather than disease-specific survival, which may be affected by bias in classifying the cause of death. Such bias may be differential according to time period.[@b17-clep-3-027]

Our study also had limitations. First, we had no data on cancer stage and thus were unable to evaluate whether the improvements in survival stemmed from better treatment or diagnosis at an earlier stage. However, data on previous stage distribution in CRC reveal no substantial change during the 2001--2008 period,[@b18-clep-3-027] thus speaking against major changes towards earlier diagnosis.[@b19-clep-3-027] Length time and lead time biases are therefore unlikely.[@b20-clep-3-027] Second, life expectancy has increased in the general population, particularly for men.[@b21-clep-3-027] Therefore, our findings of improved survival being most pronounced among men aged 80+ may partly be attributable to a reduced mortality in general. Still, Coleman et al found that the 1-year relative survival of colorectal cancer in Denmark (ie, the ratio between observed survival and expected survival based on the background mortality) improved from 71.7% to 77.7% in the period 1995--2007.[@b6-clep-3-027] This finding indicates that increased life expectancy in general is not solely responsible for the improved survival reported in our study.

A number of initiatives have been launched during the last decades to improve CRC prognosis. In 1998 the Danish Colorectal Cancer Group first published national clinical guidelines for diagnosis and treatment of CRC.[@b22-clep-3-027] Furthermore, National Cancer Plans were introduced in 2000 and 2005 aiming also to improve health care organization and avoiding delay in cancer diagnostics and treatment. According to this, the surgical treatment of CRC patients has generally been centralized. However, evidence of the impact of high hospital procedure volume and high surgeon case volume on CRC prognosis is inconsistent, although some reviews have shown benefits.[@b23-clep-3-027]--[@b25-clep-3-027] Furthermore, in rectal cancer treatment, multidisciplinary teams comprising radiologists, pathologists, surgeons, and oncologists have been established.

In addition to these initiatives, refinements over time of diagnostic procedures and techniques, such as endoscopy, computerized tomography, magnetic resonance, ultrasonic scanning, and position emission tomography may also have played a role in improving CRC diagnosis by facilitating earlier and more accurate diagnosis. However, the similar stage distribution in CRC in Denmark in the period 2001--2008[@b18-clep-3-027] indicates that these advances may only have played a minor role.

The surgical treatment of CRC has also developed over the study period, in at least three ways. First, total mesorectal excision technique was adapted in Denmark in 1996 in rectal cancer surgery. Improved survival by reduced local recurrence rate has been observed after implementation of this technique.[@b26-clep-3-027]--[@b28-clep-3-027] Second, treatment of cancer-related acute colonic obstruction by self-expanding metallic stents has been introduced.[@b29-clep-3-027] This technique has the potential of converting emergent procedures into planned procedures,[@b30-clep-3-027] which are associated with better survival.[@b31-clep-3-027]--[@b33-clep-3-027] Third, laparoscopic surgery is now widely implemented.[@b29-clep-3-027] Although randomized clinical trials on colon cancer tend to show improved short-term mortality by laparoscopic procedures compared with open surgery, long-term mortality does not differ significantly, and for rectal cancer, evidence on mortality improvements by laparoscopic surgery is less clear.[@b34-clep-3-027],[@b35-clep-3-027] In addition to the potential improvements in surgical treatment, better perioperative care may also have contributed to the observed survival improvements. Furthermore, during the study period, an oxaliplatin-containing adjuvant chemotherapy regimen has been introduced in the treatment of colonic cancer[@b36-clep-3-027]--[@b38-clep-3-027] as well as biological monoclonal antibodies to selected patients with metastatic CRC.[@b39-clep-3-027],[@b40-clep-3-027] For rectal cancer, preoperative radiotherapy with or without concomitant chemotherapy has been introduced. However, randomized clinical trials show lower local recurrence rate, but no effect on survival.[@b41-clep-3-027],[@b42-clep-3-027]

The results from our study extend those from previous population-based studies based on data from the DNRP[@b43-clep-3-027] and the Danish Cancer Registry.[@b6-clep-3-027],[@b7-clep-3-027],[@b44-clep-3-027] Compared with our Nordic counterparts and countries with similar health systems, CRC survival in Denmark is still inferior despite the reported improvements.[@b6-clep-3-027],[@b7-clep-3-027] This underlines the need of further initiatives, although we may await effects of the National Cancer Plans already implemented.

Conclusion
==========

In conclusion, survival after colon and rectal cancer has improved in central and northern Denmark during the 1998-- 2009 period. Accordingly, 30-day postoperative mortality after colon and rectal cancer has also improved.

**Disclosure**

The authors report no conflicts of interest in this work.

Surgery codes for colon cancer resections were JFB20-97 and JFHxx, and for colon cancer first operative procedure, JFA68, JFA83--84, JFA96--97, JFCxx, JFF10--13, JFF20--31, JFWxx. Similarly, surgery codes for rectal resections were JGB00--50 and JGB96--97, and for rectal, first surgical procedures were JGA32--52, JGA73--96, JGA98, JGWxx, JFF10--13, JFF20--31, and JFA68.

![Survival curves for patients with a first-time diagnosis of colon and rectal cancer.](clep-3-027f1){#f1-clep-3-027}

###### 

One- and 5-year survival and MRRs (and 95% CIs) after colon and rectal cancer diagnosis according to the time periods

                                                   Year of diagnosis                                                                                     
  ------------------------------------------------ ------------------- ------------------- ------------------------------------------------------------- -------------------------------------------------------------
  **Colon cancer**                                                                                                                                       
   Number of cancer patients                       2097                2160                2392                                                          2763
   Median age (years)                              73                  73                  73                                                            72
   **1-year**                                                                                                                                            
   Survival                                        65% (63%--67%)      67% (64%--68%)      69% (68%--71%)                                                70% (68%--71%)
   MRR                                             1 (reference)       0.96 (0.87--1.06)   0.85 (0.77--0.94)                                             0.84 (0.76--0.93)
   MRR[a](#tfn1-clep-3-027){ref-type="table-fn"}   1 (reference)       0.97 (0.88--1.08)   0.85 (0.77--0.94)                                             0.83 (0.76--0.92)
   **5-year**                                                                                                                                            
   Survival                                        37% (35%--39%)      40% (38%--42%)      43% (41%--45%)[b](#tfn2-clep-3-027){ref-type="table-fn"}      43% (41%--45%)[b](#tfn2-clep-3-027){ref-type="table-fn"}
   MRR                                             1 (reference)       0.93 (0.86--1.00)   0.85 (0.79--0.92)[b](#tfn2-clep-3-027){ref-type="table-fn"}   0.84 (0.78--0.91)[b](#tfn2-clep-3-027){ref-type="table-fn"}
   MRR[a](#tfn1-clep-3-027){ref-type="table-fn"}   1 (reference)       0.93 (0.86--1.00)   0.85 (0.78--0.91)[b](#tfn2-clep-3-027){ref-type="table-fn"}   0.84 (0.78--0.90)[b](#tfn2-clep-3-027){ref-type="table-fn"}
  **Rectal cancer**                                                                                                                                      
   Number of cancer patients                       1336                1396                1399                                                          1554
   Median age (years)                              71                  70                  69                                                            69
   **1-year**                                                                                                                                            
   Survival                                        73% (70%--75%)      74% (72%--76%)      76% (73%--78%)                                                78% (76%--80%)
   MRR                                             1 (reference)       0.94 (0.82--1.09)   0.89 (0.77--1.03)                                             0.77 (0.66--0.89)
   MRR[a](#tfn1-clep-3-027){ref-type="table-fn"}   1 (reference)       0.97 (0.84--1.13)   0.91 (0.78--1.05)                                             0.79 (0.68--0.91)
   **5-year**                                                                                                                                            
   Survival                                        39% (36%--42%)      43% (40%--46%)      46% (43%--48%)[b](#tfn2-clep-3-027){ref-type="table-fn"}      47% (45%--50%)[b](#tfn2-clep-3-027){ref-type="table-fn"}
   MRR                                             1 (reference)       0.90 (0.82--1.00)   0.84 (0.77--0.93)[b](#tfn2-clep-3-027){ref-type="table-fn"}   0.79 (0.72--0.88)[b](#tfn2-clep-3-027){ref-type="table-fn"}
   MRR[a](#tfn1-clep-3-027){ref-type="table-fn"}   1 (reference)       0.92 (0.83--1.02)   0.85 (0.77--0.94)[b](#tfn2-clep-3-027){ref-type="table-fn"}   0.81 (0.73--0.89)[b](#tfn2-clep-3-027){ref-type="table-fn"}

**Notes:** adjusted for age and gender;

predicted values.

**Abbreviations:** CI, confidence interval; MRR, mortality rate ratio.

###### 

One- and 5-year survival after colon cancer diagnosis according to age at diagnosis and time periods

  Age (years)                               Year of diagnosis                                                                               
  ------------- --------------------------- ------------------- ---------------- ---------------------------------------------------------- ----------------------------------------------------------
  **Men**                                                                                                                                   
  15--64        Number of cancer patients   282                 323              346                                                        401
                1-year survival             74% (69%--79%)      77% (72%--81%)   80% (75%--84%)                                             80% (76%--84%)
                5-year survival             45% (39%--50%)      45% (40%--50%)   54% (49%--59%)[a](#tfn4-clep-3-027){ref-type="table-fn"}   56% (50%--61%)[a](#tfn4-clep-3-027){ref-type="table-fn"}
  65--79        Number of cancer patients   484                 502              562                                                        691
                1-year survival             66% (61%--70%)      64% (60%--68%)   70% (66%--73%)                                             70% (66%--73%)
                5-year survival             36% (32%--40%)      39% (35%--43%)   42% (38%--46%)[a](#tfn4-clep-3-027){ref-type="table-fn"}   41% (37%--45%)[a](#tfn4-clep-3-027){ref-type="table-fn"}
  80+           Number of cancer patients   208                 228              247                                                        310
                1-year survival             49% (42%--56%)      54% (47%--60%)   59% (53%--65%)                                             57% (51%--63%)
                5-year survival             17% (13%--23%)      27% (21%--33%)   24% (19%--29%)[a](#tfn4-clep-3-027){ref-type="table-fn"}   22% (17%--27%)[a](#tfn4-clep-3-027){ref-type="table-fn"}
  **Women**                                                                                                                                 
  15--64        Number of cancer patients   294                 314              300                                                        395
                1-year survival             76% (71%--81%)      82% (77%--85%)   80% (75%--84%)                                             78% (73%--82%)
                5-year survival             48% (42%--53%)      53% (48%--59%)   57% (51%--63%)[a](#tfn4-clep-3-027){ref-type="table-fn"}   54% (49%--59%)[a](#tfn4-clep-3-027){ref-type="table-fn"}
  65--79        Number of cancer patients   503                 489              574                                                        570
                1-year survival             68% (63%--71%)      68% (64%--72%)   74% (70%--77%)                                             73% (69%--76%)
                5-year survival             43% (38%--47%)      43% (38%--47%)   49% (45%--53%)[a](#tfn4-clep-3-027){ref-type="table-fn"}   48% (44%--52%)[a](#tfn4-clep-3-027){ref-type="table-fn"}
  80+           Number of cancer patients   326                 304              363                                                        396
                1-year survival             52% (46%--57%)      51% (46%--57%)   50% (45%--55%)                                             55% (50%--60%)
                5-year survival             25% (21%--30%)      29% (24%--34%)   27% (22%--31%)[a](#tfn4-clep-3-027){ref-type="table-fn"}   31% (26%--36%)[a](#tfn4-clep-3-027){ref-type="table-fn"}

**Note:** predicted values.

###### 

Thirty-day mortality and 30-day MRRs (and 95% CIs) after resection or first surgical procedure in colon and rectal cancer patients

                                                          Year of surgery                                           
  ------------------------------------------------------- ----------------- ------------------- ------------------- -------------------
  **Colon cancer**                                                                                                  
   **Resection**                                                                                                    
   Number of cancer patients                              1471              1507                1674                1690
   Median age (years)                                     73                72                  72                  72
   30-day mortality                                       9% (8%--11%)      10% (9%--12%)       7% (6%--8%)         7% (5%--8%)
   30-day MRR                                             1 (reference)     1.12 (0.89--1.41)   0.71 (0.55--0.91)   0.69 (0.53--0.88)
   30-day MRR[a](#tfn5-clep-3-027){ref-type="table-fn"}   1 (reference)     1.14 (0.91--1.44)   0.71 (0.55--0.91)   0.68 (0.53--0.87)
   **First surgical procedure**                                                                                     
   Number of cancer patients                              1622              1615                1803                1880
   Median age (years)                                     73                73                  73                  72
   30-day mortality                                       11% (9%--12%)     12% (10%--13%)      8% (7%--10%)        8% (7%--9%)
   30-day MRR                                             1 (reference)     1.09 (0.89--1.34)   0.74 (0.60--0.92)   0.71 (0.57--0.88)
   30-day MRR[a](#tfn5-clep-3-027){ref-type="table-fn"}   1 (reference)     1.12 (0.91--1.38)   0.75 (0.60--0.93)   0.71 (0.57--0.88)
  **Rectal cancer**                                                                                                 
   **Resection**                                                                                                    
   Number of cancer patients                              865               852                 773                 890
   Median age (years)                                     70                69                  68                  68
   30-day mortality                                       5% (4%--7%)       5% (4%--7%)         5% (4%--7%)         3% (2%--4%)
   30-day MRR                                             1 (reference)     0.95 (0.63--1.44)   1.00 (0.66--1.53)   0.54 (0.34--0.88)
   30-day MRR[a](#tfn5-clep-3-027){ref-type="table-fn"}   1 (reference)     1.06 (0.70--1.61)   1.04 (0.68--1.58)   0.59 (0.37--0.96)
   **First surgical procedure**                                                                                     
   Number of cancer patients                              1025              1019                937                 1087
   Median age (years)                                     71                70                  69                  69
   30-day mortality                                       7% (5%--8%)       6% (5%--8%)         7% (5%--9%)         4% (3%--5%)
   30-day MRR                                             1 (reference)     0.95 (0.67--1.33)   1.02 (0.73--1.43)   0.56 (0.38--0.83)
   30-day MRR[a](#tfn5-clep-3-027){ref-type="table-fn"}   1 (reference)     1.02 (0.73--1.43)   1.05 (0.75--1.48)   0.61 (0.41--0.89)

**Note:** adjusted for age and gender.

**Abbreviations:** CI, confidence interval; MRR, mortality rate ratio.

###### 

One- and 5-year survival after rectal cancer diagnosis according to age at diagnosis and time periods

  Age (years)                               Year of diagnosis                                                                               
  ------------- --------------------------- ------------------- ---------------- ---------------------------------------------------------- ----------------------------------------------------------
  **Men**                                                                                                                                   
  15--64        Number of cancer patients   248                 301              315                                                        338
                1-year survival             84% (79%--88%)      82% (78%--86%)   83% (79%--87%)                                             89% (85%--92%)
                5-year survival             53% (47%--59%)      53% (47%--58%)   54% (48%--59%)[a](#tfn7-clep-3-027){ref-type="table-fn"}   58% (52%--63%)[a](#tfn7-clep-3-027){ref-type="table-fn"}
  65--79        Number of cancer patients   343                 367              383                                                        427
                1-year survival             72% (67%--77%)      71% (66%--75%)   72% (68%--77%)                                             78% (74%--82%)
                5-year survival             37% (32%--42%)      40% (35%--45%)   42% (37%--47%)[a](#tfn7-clep-3-027){ref-type="table-fn"}   45% (40%--50%)[a](#tfn7-clep-3-027){ref-type="table-fn"}
  80+           Number of cancer patients   133                 117              128                                                        146
                1-year survival             48% (39%--56%)      60% (50%--68%)   55% (46%--64%)                                             63% (54%--70%)
                5-year survival             14% (8%--20%)       24% (17%--32%)   22% (16%--30%)[a](#tfn7-clep-3-027){ref-type="table-fn"}   23% (16%--31%)[a](#tfn7-clep-3-027){ref-type="table-fn"}
  **Women**                                                                                                                                 
  15--64        Number of cancer patients   191                 215              210                                                        252
                1-year survival             82% (76%--87%)      89% (84%--92%)   91% (87%--95%)                                             87% (83%--91%)
                5-year survival             54% (46%--61%)      59% (52%--65%)   66% (59%--72%)[a](#tfn7-clep-3-027){ref-type="table-fn"}   63% (56%--68%)[a](#tfn7-clep-3-027){ref-type="table-fn"}
  65--79        Number of cancer patients   292                 267              229                                                        256
                1-year survival             76% (71%--81%)      73% (67%--78%)   75% (69%--80%)                                             77% (71%--82%)
                5-year survival             40% (35%--46%)      43% (37%--49%)   48% (42%--54%)[a](#tfn7-clep-3-027){ref-type="table-fn"}   49% (43%--55%)[a](#tfn7-clep-3-027){ref-type="table-fn"}
  80+           Number of cancer patients   129                 129              134                                                        135
                1-year survival             57% (48%--65%)      57% (48%--65%)   61% (52%--69%)                                             55% (46%--63%)
                5-year survival             19% (13%--27%)      20% (14%--27%)   25% (18%--32%)[a](#tfn7-clep-3-027){ref-type="table-fn"}   22% (15%--29%)[a](#tfn7-clep-3-027){ref-type="table-fn"}

**Note:** predicted values.
